In conclusion, our study suggests that for patients with advanced NSCLC with EGFR mutations and PD-L1 TPS ≥ 50% who have failed prior EGFR-TKI therapies without T790M mutation, ICI-based treatment could provide more favorable survival than classical chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.